Treatment Action Group

Webinar: From evidence to action: Community-led monitoring for access to TB screening and diagnostic testing

Treatment Action Group and the Coalition of Women Living with HIV and AIDS (COWLHA) will host a webinar on 4 May 2022 explaining how community-led monitoring can be used to generate evidence for advocacy to improve the availability, accessibility, acceptability, and quality of TB screening and diagnostic services. 

Read More →

Community-led monitoring for access to TB screening and diagnostic testing

A tool, developed by the Coalition of Women Living with HIV and AIDS in partnership with Treatment Action Group, designed to equip communities to use community-lead monitoring to better understand the TB screening and diagnostic services, and to translate findings into evidence-based advocacy.

Read More →

#RightToPreventTB campaign: TB preventive treatment is a human right!

The #RightToPreventTB campaign focuses attention on the urgent need to scale-up TB preventive treatment as a matter of human rights.

Read More →

CROI 2022 TB round up

Treatment Action Group (TAG) released an overview of TB data reported at the 29th Conference on Retroviruses and Opportunistic Infections (CROI 2022) held virtually on 12-16 February 2022. A summary of major findings and TAG’s take on them are available here.

Read More →

European commitments to TB R&D investments: Promises made to be broken?

A brief, released by Treatment Action Group, outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.

Read More →

TAG's 2021 Pipeline Report: TB chapters released

Treatment Action Group (TAG) launches newly available TB chapters of its 2021 Pipeline Report.

Read More →

Hepatitis C and TB Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access

Treatment Action Group releases a patent landscape investigating potential patent barriers for the development and delivery of long-acting formulations for selected hepatitis C and TB medicines.

Read More →

Webinar on long-acting technologies

On 4 November 2021, Treatment Action Group (TAG) and the International Treatment Preparedness Coalition (ITPC) will co-host a webinar, 'Same Meds, New Patents: What Do Activists Need to Know About Long-Acting Technologies', to present the main findings of the upcoming report 'Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis on Patenting Trends.'

Read More →

An Activist’s Guide to Shorter Treatment for Drug-Sensitive TB

This new resource provides activists with information about two shorter treatment regimens for drug-sensitive TB, and equips them with actions they can take and arguments they can use to advocate for access to those regimens.

Read More →

TAGline: Delivering on the promise of long-acting formulations

October 2021 issue of TAGline delves deep into the development of long-acting formulations for the treatment and prevention of HIV, TB, hepatitis C, and malaria.

Read More →

Page 2 of 20 · Total posts: 10

←First 1 2 3 Last→